Therefore, immunogenicity of tumours is presumably the crucial factor to affect the potency of TGF-β antagonism on the specific cellular targets in anti-tumour therapy; nevertheless enhancement of CD8+ T-cell mediated anti-tumour immune response is the main outcome of TGF-β antagonism even in the non-immunogenic tumour. This evidence concerns the gene CD8A and neoplasm.